MikeTrendsTrends right now
AI: reposAPI

search

pharmaceutical companies

Trends

  1. 1
    Kobayashi Pharmaceutical weighs takeover offer worth over ¥500 billion●Kobayashi Pharmaceutical, the firm that was at the center of a supplement contamination scandal involving suspected deatMmastodonBusinessMarkets458 min ago

    Kobayashi Pharmaceutical, the Japanese maker at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer valued at more than ¥500 billion. The possible deal comes as the company continues to face fallout from the scandal, which damaged its reputation and finances.

  2. 2
    European Capital Backs Colombian Biotech Firm for 250 Million Vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines✉newsWorldEU Politics1 h ago

    European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal positions Colombia as a growing player in global vaccine manufacturing and reflects Europe's interest in diversifying pharmaceutical production capacity beyond its borders, though details on the funding amount and timeline remain limited.

  3. 3
    Afghan inspectors check 75 medicine importers in Kabul●75 medicine importers inspected in Kabul✉newsHealthMedicine27 min ago

    Authorities in Kabul have carried out inspections of 75 medicine importers, according to Pajhwok Afghan News. The checks target companies bringing pharmaceutical products into Afghanistan, a sector long plagued by concerns over counterfeit and substandard drugs. The report has drawn attention regionally as Afghans follow efforts to improve oversight of the medicine supply chain.

  4. 4
    Arrowhead Pharmaceuticals Stock Nears Five-Year High on Phase 3 Win▼ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval✉newsBusinessRetail3 h ago

    Arrowhead Pharmaceuticals shares are on track to reach their highest level in more than five years after positive Phase 3 trial results, with retail investors celebrating the biotech's momentum. The company is reportedly aiming for a broader FDA approval than initially expected, fueling optimism about the commercial potential of its drug pipeline and driving renewed interest in the stock.